New combo aims to tame deadly transplant complication with fewer steroids
NCT ID NCT05123040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) in 10 people with a severe form of acute graft-versus-host disease (aGVHD), a complication that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to reduce side effects while still controlling the disease. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lung protein tame severe graft-versus-host disease?
- Combination drug approach aims to tame immune attack after stem cell transplant
- New shot may shield transplant patients from deadly immune attack
- New drug shows promise in controlling transplant complications
- Poop pills may tame deadly transplant complication
- JAKAVI under the microscope: new study tracks GVHD treatment in real life